Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of HLX43 (Anti-PD-L1 ADC) in Advanced/Metastatic Solid Tumors
jRCT2021250029Phase 1Recruiting
- Sponsor
- Henlius
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label trial of HLX43 in Nonhematologic neoplasms and thymic carcinoma (TC) (2 arms), sponsored by Henlius. Primary endpoints: RP2D of HLX43 in NSCLC or TC patients and Objective response rate (ORR) by IRRC. Started Mar 2026; status: recruiting.
02
Drugs
HLX43
03
Conditions
Nonhematologic neoplasmsthymic carcinoma (TC)
Beyond the preview
Go deeper on jRCT2021250029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021250029.